VXRT - NASDAQ

Vaxart, Inc.

VXRT·NASDAQ

$0.60

+0.083%

HealthcareBiotechnology

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$145.98M

EPS0.0700

P/E Ratio4.94

Earnings Date05/12/2026

186.08M

Assets

12%

3Y+21.0%

5Y+22.0%

10Y+364.0%

98.28M

Total Liabilities

-9%

3Y+127.0%

5Y+237.0%

10Y+359.0%

87.80M

Total Equity

49%

3Y-21.0%

5Y-29.0%

10Y+370.0%

Vaxart, Inc. Funding & Solvency Profile

VXRT · NASDAQ

Current Assets

Cash & Cash Equivalents53.81M

Net Receivables51.34M

Inventory0.00

Other Current Assets0.00

Total Current Assets115 M

Non-Current Assets

Property, Plant & Equipment25.85M

Goodwill & Intangible Assets7.33M

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets26 M

Total Assets

186.08M

Financial Health Analysis

Current Ratio

5.34x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.12x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

94 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

62% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Vaxart, Inc. Balance Sheet

VXRT • NASDAQ

Vaxart, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Jun 2017	Jun 2016	Jun 2015	Jun 2014	Jun 2013	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	53.8M	25.2M	34.8M	44M	143.7M	126.9M	13.5M	11.5M	1.6M	17.7M	49.7M	44.7M	81.7M	66.8M	94.3M	53.6M	59.5M	106.4M	217.6M	86.2M
Short-Term Investments	10M	26.5M	5M	49.7M	22.7M	0.0	0.0	0.0	1.4M	20.9M	19.3M	12.9M	0.0	0.0	2.1M	54.6M	59.5M	23.9M	1.6M	32.5M
Cash & Short-Term Investments	63.8M	51.7M	39.7M	93.7M	166.5M	126.9M	13.5M	11.5M	3M	38.6M	69M	57.6M	81.7M	66.8M	96.4M	108.2M	119M	130.3M	219.2M	118.7M
Net Receivables	51.3M	12M	3M	20K	71K	334K	3.6M	1.8M	630K	600K	700K	12.6M	18.7M	11M	995K	1M	6.7M	0.0	2.4M	20.4M
Accounts Receivables	51.3M	12M	3M	20K	71K	334K	3.6M	1.8M	630K	600K	700K	12.6M	900K	100K	995K	0.0	0.0	0.0	2.4M	20.4M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.8M	10.9M	0.0	1M	6.7M	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.3M
Prepaids	0.0	4.3M	2.5M	3.7M	2.6M	0.0	453K	1.3M	137K	700K	293K	600K	700K	2.2M	497K	829K	1.6M	1.4M	2.4M	2.7M
Other Current Assets	0.0	318K	333K	2M	0.0	1.3M	0.0	1.3M	0.0	0.0	2.7M	600K	0.0	0.0	0.0	0.0	0.0	10.4M	2.2M	14.1M
Total Current Assets	115.2M	68.3M	45.5M	99.5M	169.2M	128.5M	17.6M	14.6M	3.8M	39.9M	72.4M	70.8M	101.1M	80M	97.9M	110M	129.7M	142.2M	226.2M	175.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	25.9M	29.1M	36.6M	41.3M	19.8M	8.3M	2.2M	1.1M	730K	200K	300K	200K	2M	4.3M	84K	597K	855K	1.3M	2M	88.3M
Goodwill	4.5M	4.5M	4.5M	4.5M	4.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	2.8M	3.6M	4.3M	5M	10.6M	15.4M	17.1M	19.4M	40K	44K	48K	0.0	0.0	600K	0.0	0.0	0.0	0.0	0.0	1.7M
Goodwill & Intangible Assets	7.3M	8.1M	8.8M	9.5M	15.1M	15.4M	17.1M	19.4M	40K	44K	48K	0.0	0.0	600K	0.0	0.0	0.0	0.0	0.0	1.7M
Long-Term Investments	0.0	0.0	0.0	0.0	16.2M	0.0	0.0	0.0	0.0	0.0	0.0	7.9M	10M	0.0	0.0	2.5M	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	500K	900K	1.5M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	61M	926K	3.6M	890K	372K	141K	103K	0.0	-44K	-48K	0.0	0.0	-600K	0.0	748K	769K	729K	10.4M	701K
Total Non-Current Assets	33.2M	98.1M	46.3M	54.4M	52M	24.1M	19.4M	20.6M	770K	200K	300K	8.6M	12.9M	5.8M	84K	3.8M	1.6M	2M	12.4M	90.7M
Other Assets	37.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	186.1M	166.4M	91.8M	153.8M	221.2M	152.6M	37M	35.2M	4.5M	40.1M	72.7M	79.4M	114M	85.8M	98M	113.9M	131.3M	144.2M	238.6M	265.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	21.5M	7M	1.6M	5.5M	3.9M	2.1M	852K	962K	1.4M	1.4M	3.9M	3.4M	21.4M	8.9M	146K	552K	1.7M	1.2M	3.6M	8M
Accounts Payable	21.5M	7M	1.6M	5.5M	3.9M	2.1M	852K	962K	1.4M	1.4M	3.9M	1.9M	2.8M	2.4M	146K	552K	1.7M	1.2M	3.6M	8M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5M	18.6M	6.5M	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	11.4M	5.6M	8.1M	5.1M	1.6M	903K	1.1M	1.5M	400K	600K	1.7M	4.6M	6.9M	1.9M	7.4M	5M	1.8M	3.2M	7.8M
Short Term Debt	3M	4.1M	3.8M	95K	836K	4.8M	0.0	1.7M	1.5M	200K	400K	200K	0.0	0.0	0.0	0.0	6M	0.0	0.0	291K
Capital Lease Obligations (Current)	0.0	3.1M	2.7M	2.2M	1M	0.0	841K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	500K	0.0	400K	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	68K	0.0	0.0	0.0	0.0	0.0	4.6M	1.5M	0.0	2.9M	3.6M	5.9M	0.0	300K	2.5M	7.8M	18.4M	0.0	0.0	16.1M
Other Current Liabilities	-3M	65.4M	0.0	2M	1.0	3.2M	2M	3.8M	88K	3.9M	4.3M	3.7M	900K	1.5M	1.7M	2.2M	2.8M	4.6M	13.4M	28.8M
Total Current Liabilities	21.6M	90.9M	13.7M	17.9M	10.8M	11.8M	9.2M	7.5M	4.5M	5.9M	9.2M	9M	26.9M	17.6M	6.3M	17.9M	33.9M	7.6M	20.3M	44.9M
NON-CURRENT LIABILITIES
Long Term Debt	6M	1.7M	2.6M	5.6M	10.7M	12.2M	0.0	1.9M	38.7M	100K	300K	800K	0.0	0.0	0.0	0.0	0.0	15.2M	71.7M	109.3M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.8M	35.4M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	439K	293K	231K	171K	109K	13.4M	14.6M	0.0	15.4M	17M	100K	200K	200K	0.0	0.0	0.0	0.0	0.0	238K
Total Non-Current Liabilities	76.7M	16.6M	20.3M	25.3M	22.9M	17.4M	14.9M	16.5M	38.7M	15.5M	17.3M	900K	200K	200K	32.8M	35.4M	0.0	15.2M	71.7M	109.6M
Capital Lease Obligations	6M	17.5M	20.1M	21.7M	13M	5.2M	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	98.3M	107.5M	34M	43.3M	33.6M	29.2M	24.1M	24M	43.2M	21.4M	26.5M	9.9M	27.1M	17.8M	39.1M	53.3M	33.9M	22.8M	92M	154.5M
SHAREHOLDERS' EQUITY
Treasury Stock	-159K	-350K	-366K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-92.6M	-92.6M	-50.3M	-42.2M	-23.6M	-5.3M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K	1K	1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	24K	23K	15K	13K	13K	11K	5K	714K	0.0	3.9M	3.9M	3.9M	3.5M	2.8M	6.4M	6.3M	6.3M	6.2M	6.2M	6.1M
Additional Paid-In Capital	548.1M	535.8M	467.7M	438M	406.9M	272.3M	129.6M	108.5M	41.3M	159.6M	157.6M	155.6M	146.4M	118.7M	373.2M	370.4M	365.8M	363M	333.5M	327.2M
Retained Earnings	-460.2M	-476.5M	-409.6M	-327.1M	-219.4M	-148.9M	-116.7M	-98M	-80M	-163.8M	-134.3M	-108.9M	-89.8M	-78.8M	-228.1M	-223.5M	-224.4M	-205.7M	-169.6M	-216.7M
Accumulated Other Comprehensive Income/Loss	-3K	4K	-1K	-299K	-74K	0.0	0.0	0.0	0.0	19M	19M	18.9M	26.8M	25.3M	0.0	-3K	-20K	60K	0.0	0.0
Total Stockholders' Equity	87.8M	58.9M	57.8M	110.6M	187.5M	123.4M	13M	11.2M	-38.7M	18.7M	46.2M	69.5M	86.9M	68M	58.9M	60.6M	97.4M	121.4M	146.5M	111.4M
Total Equity	87.8M	58.9M	57.8M	110.6M	187.5M	123.4M	13M	11.2M	-38.7M	18.7M	46.2M	69.5M	86.9M	68M	58.9M	60.6M	97.4M	121.4M	146.5M	111.4M
SUMMARY
Total Liabilities & Equity	186.1M	166.4M	91.8M	153.8M	221.2M	152.6M	37M	35.2M	4.5M	40.1M	72.7M	79.4M	114M	85.8M	98M	113.9M	131.3M	144.2M	238.6M	265.9M
Total Investments	10M	26.5M	5M	49.7M	39M	0.0	0.0	0.0	1.4M	20.9M	19.3M	20.8M	10M	0.0	2.1M	57.1M	59.5M	23.9M	1.6M	32.5M
Total Debt	9M	23.3M	26.5M	27.4M	24.5M	22.1M	2.3M	3.6M	40.3M	300K	700K	1M	0.0	0.0	0.0	0.0	6M	15.2M	71.7M	109.6M
Net Debt	-44.8M	-1.9M	-8.2M	-16.6M	-119.2M	-104.7M	-11.2M	-7.8M	38.7M	-17.4M	-49M	-43.7M	-81.7M	-66.8M	-94.3M	-53.6M	-53.6M	-91.2M	-145.9M	23.4M
Shares Outstanding	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064	228,919,064

SEC Filings

VXRT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 19, 2026	May 19, 2026	2026	View Filing
S-1/A S-1/A (Amended) N/A	May 18, 2026	May 18, 2026		View Filing
S-1 S-1 N/A	May 08, 2026	May 08, 2026		View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 21, 2026	April 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 17, 2026	April 16, 2026	2026	View Filing
S-3 S-3 N/A	April 16, 2026	April 16, 2026		View Filing

Showing 1 to 10 of 589 filings

Related Guides

Blog Categories

Continue your VXRT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.